ONA, OTCQBNANF) CEO David Regan talked with Proactive about the company's latest step in advancing its targeted hyperthermia therapy (THT) towards market approval. Speaking from a major biotech conference in Boston, Regan shared details on a newly signed clinical trial agreement in Chile. 